Intensity Therapeutics is a clinical-stage biotechnology company engaged in developing anti-cancer immune activation. Co.'s proprietary technology platform, DfuseRxSM involves the direct injection into tumors and diffuse therapeutic agents into cancer cells. Co.'s lead product candidate, INT230-6 consists of two anti-cancer cytotoxic agents, cisplatin and vinblastine sulfate, mixed in water with the amphiphilic molecule (SHAO) is used for sarcoma, breast and also lung cancer. The INTS YTD return is shown above.
The YTD Return on the INTS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether INTS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the INTS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|